Substance abuse, hepatitis C, and aging in HIV: common cofactors that contribute to neurobehavioral disturbances

References

• Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011; 17(1):3–16.
   PubMed Web of Science ®Google Scholar
• Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr. 2007;45(2):174–182.
   PubMed Web of Science ®Google Scholar
• Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol. 2004;10(6):350–357.
   PubMed Web of Science ®Google Scholar
• Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010; 24(9):1243–1250.
   PubMed Web of Science ®Google Scholar
• Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10(3):317–331.
   PubMed Web of Science ®Google Scholar
• Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. J Neurovirol. 2002;59(12):1944–1950.
   Google Scholar
• Marcotte TD, Wolfson T, Rosenthal TJ, et al. A multimodal assessment of driving performance in HIV infection. Neurology. 2004;63(8): 1417–1422.
   PubMed Web of Science ®Google Scholar
• Thames AD, Becker BW, Marcotte TD, et al. Depression, cognition, and self-appraisal of functional abilities in HIV: an examination of subjective appraisal versus objective performance. Clin Neuropsychol. 2011;25(2): 224–243.
   PubMed Web of Science ®Google Scholar
• Munakata J, Benner JS, Becker S, Dezii CM, Hazard EH, Tierce JC. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus. Med Care. 2006;44(10):893–899.
   PubMed Web of Science ®Google Scholar
• Heaton RK, Grant I, Butters N, et al. The HNRC 500 – neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1(3): 231–251.
   PubMedGoogle Scholar
• Reger M, Welsh R, Razani J, Martin DJ, Boone KB. A meta-analysis of the neuropsychological sequelae of HIV infection. J Int Neuropsychol Soc. 2002;8(3):410–424.
   PubMed Web of Science ®Google Scholar
• Ances BM, Vaida F, Yeh MJ, et al. HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis. 2010;201(3):336–340.
   Web of Science ®Google Scholar
• Chang L, Speck O, Miller EN, et al. Neural correlates of attention and working memory deficits in HIV patients. Neurology. 2001;57(6): 1001–1007.
   PubMed Web of Science ®Google Scholar
• Cohen RA, Harezlak J, Schifitto G, et al. Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol. 2010;16(1):25–32.
   PubMed Web of Science ®Google Scholar
• Jernigan TL, Archibald S, Hesselink JR, et al. Magnetic resonance imaging morphometric analysis of cerebral volume loss in human immunodeficiency virus infection. The HNRC Group. Arch Neurol. 1993;50(3):250–255.
   PubMedGoogle Scholar
• Castelo JM, Sherman SJ, Courtney MG, Melrose RJ, Stern CE. Altered hippocampal-prefrontal activation in HIV patients during episodic memory encoding. Neurology. 2006;66(11):1688–1695.
   PubMed Web of Science ®Google Scholar
• Klunder AD, Chiang MC, Dutton RA, et al. Mapping cerebellar degeneration in HIV/AIDS. Neuroreport. 2008;19(17):1655–1659.
   Web of Science ®Google Scholar
• Moore DJ, Masliah E, Rippeth JD, et al. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS. 2006;20(6):879–887.
   PubMed Web of Science ®Google Scholar
• Thompson PM, Dutton RA, Hayashi KM, et al. 3D mapping of ventricular and corpus callosum abnormalities in HIV/AIDS. Neuroimage. 2006;31(1):12–23.
   Web of Science ®Google Scholar
• Galvan FH, Burnam MA, Bing EG. Co-occurring psychiatric symptoms and drug dependence or heavy drinking among HIV-positive people. J Psychoactive Drugs. 2003;35(Suppl 1):S153–S160.
   PubMed Web of Science ®Google Scholar
• Rabkin JG, McElhiney MC, Ferrando SJ. Mood and substance use disorders in older adults with HIV/AIDS: methodological issues and preliminary evidence. AIDS. 2004;18 (Suppl 1):S43–S48.
   PubMedGoogle Scholar
• Center for Disease Control and Prevention. Fact Sheet: Estimates of New HIV Infections in the United States. 2008; Available from: http://www.cdc.gov/hiv/topics/surveillance/resources/factsheets/pdf/incidence.pdf. Accessed August 4, 2011.
   Google Scholar
• Center for Disease Control and Prevention. Fact Sheet: HIV and AIDS in the United States. 2010; Available from: http://www.cdc.gov/hiv/resources/factsheets/PDF/us.pdf. Accessed August 4, 2011.
   Google Scholar
• Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733–1745.
   PubMed Web of Science ®Google Scholar
• Cohn SE, Jiang H, McCutchan JA, et al. Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care. 2011;23(6):775–785.
   PubMed Web of Science ®Google Scholar
• Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2011. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Brinkman WJ, Hall DM, Suo JL, Weber RJ. Centrally-mediated opioid-induced immunosuppression. Elucidation of sympathetic nervous system involvement. Adv Exp Med Biol. 1998;437:43–49.
   PubMed Web of Science ®Google Scholar
• Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther. 2004;11(5):354–365.
   PubMedGoogle Scholar
• Donahoe RM, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol. 1998;83(1–2): 77–87.
   PubMed Web of Science ®Google Scholar
• Kumar R, Torres C, Yamamura Y, et al. Modulation by morphine of viral set point in rhesus macaques infected with simian immunodeficiency virus and simian-human immunodeficiency virus. J Virol. 2004;78(20): 11425–11428.
   Web of Science ®Google Scholar
• Bokhari SM, Hegde R, Callen S, et al. Morphine Potentiates Neuropathogenesis of SIV Infection in Rhesus Macaques. J Neuroimmune Pharmacol. 2011;6(4):626–639.
   Web of Science ®Google Scholar
• Peterson PK, Gekker G, Hu S, Lokensgard J, Portoghese PS, Chao CC. Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures: implication of an atypical mu-opioid receptor. Neuropharmacology. 1999;38(2):273–278.
   PubMed Web of Science ®Google Scholar
• Schweitzer C, Keller F, Schmitt MP, et al. Morphine stimulates HIV replication in primary cultures of human Kupffer cells. Res Virology. 1991;142(2–3):189–195.
   PubMedGoogle Scholar
• Quang-Cantagrel ND, Wallace MS, Ashar N, Mathews C. Long-term methadone treatment: effect on CD4+ lymphocyte counts and HIV-1 plasma RNA level in patients with HIV infection. Eur J Pain. 2001; 5(4):415–420.
   PubMed Web of Science ®Google Scholar
• Wang AX, Li TS, Cao YZ, Han Y, Qiu ZF, Xie J. T-cell response of advanced aids patients after highly active antiretroviral therapy. Chin Med Sci J. 2005;20(4):223–225.
   Google Scholar
• Bell JE, Donaldson YK, Lowrie S, et al. Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. AIDS. 1996;10(5):493–499.
   Web of Science ®Google Scholar
• Davies J, Everall IP, Weich S, McLaughlin J, Scaravilli F, Lantos PL. HIV-associated brain pathology in the United Kingdom: an epidemiological study. AIDS. 1997;11(9):1145–1150.
   PubMed Web of Science ®Google Scholar
• Morgello S, Mahboob R, Yakoushina T, Khan S, Hague K. Autopsy findings in a human immunodeficiency virus-infected population over 2 decades: influences of gender, ethnicity, risk factors, and time. Arch Pathol Lab Med. 2002;126(2):182–190.
   PubMed Web of Science ®Google Scholar
• Nath A, Hauser KF, Wojna V, et al. Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr. 2002;31(Suppl 2):S62–S69.
   PubMed Web of Science ®Google Scholar
• Spijkerman IJ, Langendam MW, Veugelers PJ, et al. Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion. Epidemiology. 1996;7(6):571–577.
   PubMed Web of Science ®Google Scholar
• Thorpe LE, Frederick M, Pitt J, et al. Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women. J Acquir Immune Defic Syndry. 2004;37(3):1423–1430.
   Web of Science ®Google Scholar
• Everall IP. Interaction between HIV and intravenous heroin abuse? J Neuroimmunol. 2004;147(1–2):13–15.
   PubMed Web of Science ®Google Scholar
• Nath A. Human immunodeficiency virus-associated neurocognitive disorder: pathophysiology in relation to drug addiction. Ann NY Acad Sci. 2010;1187:122–128.
   Web of Science ®Google Scholar
• Bell JE, Brettle RP, Chiswick A, Simmonds P. HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain. 1998;121(Pt 11):2043–2052.
   PubMedGoogle Scholar
• Bouwman FH, Skolasky RL, Hes D, et al. Variable progression of HIV-associated dementia. Neurology. 1998;50(6):1814–1820.
   Web of Science ®Google Scholar
• Starace F, Baldassarre C, Biancolilli V, et al. Early neuropsychological impairment in HIV-seropositive intravenous drug users: evidence from the Italian Multicentre Neuropsychological HIV Study. Acta Psychiatr Scand. 1998;97(2):132–138.
   Web of Science ®Google Scholar
• Applebaum AJ, Otto MW, Richardson MA, Safren SA. Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients. J Clin Exp Neuropsyc. 2010;32(6):579–589.
   PubMed Web of Science ®Google Scholar
• Bartok JA, Martin EM, Pitrak DL, et al. Working memory deficits in HIV-seropositive drug users. J Int Neuropsychol Soc. 1997;3(5):451–456.
   PubMed Web of Science ®Google Scholar
• Wellman MC. Neuropsychological impairment among intravenous drug users in pre-AIDS stages of HIV infection. Int J Neurosci. 1992;64(1–4):183–194.
   PubMed Web of Science ®Google Scholar
• Ayuso-Mateos JL, Pereda M, Gomez Del Barrio A, Echevarria S, Farinas MC, Garcia-Palomo D. Slowed reaction time in HIV-1-seropositive intravenous drug users without AIDS. Eur Neurol. 2000;44(2):72–78.
   PubMed Web of Science ®Google Scholar
• Del Pesce M, Franciolini B, Censori B, et al. Cognitive behavior in asymptomatic (CDC stage II and III) HIV – seropositive intravenous drug users (IVDUs). Ital J Neurol Sci. 1993;14(9):619–625.
   PubMedGoogle Scholar
• Rodriguez Salgado D, Rodriguez Alvarez M, Seoane Pesqueira G. Neuropsychological impairment among asymptomatic HIV-positive former intravenous drug users. Cogn Behav Neurol. 2006;19(2):95–104.
   Web of Science ®Google Scholar
• McKegney FP, O’Dowd MA, Feiner C, Selwyn P, Drucker E, Friedland GH. A prospective comparison of neuropsychologic function in HIV-seropositive and seronegative methadone-maintained patients. AIDS. 1990;4(6):565–569.
   Web of Science ®Google Scholar
• Silberstein CH, McKegney FP, O’Dowd MA, et al. A prospective longitudinal study of neuropsychological and psychosocial factors in asymptomatic individuals at risk for HTLV-III/LAV infection in a methadone program: preliminary findings. Int J Neurosci. 1987;32(3–4): 669–676.
   PubMed Web of Science ®Google Scholar
• Margolin A, Avants SK, Warburton LA, Hawkins KA. Factors affecting cognitive functioning in a sample of human immunodeficiency virus-positive injection drug users. AIDS Patient Care STDS. 2002;16(6): 255–267.
   PubMed Web of Science ®Google Scholar
• Avants SK, Margolin A, Warburton LA, Hawkins KA, Shi J. Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. Am J Addiction. 2001;10(1):69–78.
   PubMed Web of Science ®Google Scholar
• Waldrop-Valverde D, Ownby RL, Wilkie FL, Mack A, Kumar M, Metsch L. Neurocognitive aspects of medication adherence in HIV-positive injecting drug users. AIDS Behav. 2006;10(3):287–297.
   PubMed Web of Science ®Google Scholar
• Hestad K, Aukrust P, Ellertsen B, Klove H, Wilberg K. Neuropsychological deficits in HIV-1 seropositive and seronegative intravenous drug users. J Clin Exp Neuropsyc. 1993;15(5):732–742.
   PubMed Web of Science ®Google Scholar
• Concha M, Selnes OA, Vlahov D, et al. Comparison of neuropsychological performance between AIDS-free injecting drug users and homosexual men. Neuroepidemiology. 1997;16(2):78–85.
   PubMed Web of Science ®Google Scholar
• Farinpour R, Martin EM, Seidenberg M, et al. Verbal working memory in HIV-seropositive drug users. J Int Neuropsychol Soc. 2000;6(5): 548–555.
   PubMed Web of Science ®Google Scholar
• Selnes OA, McArthur JC, Royal W 3rd, et al. HIV-1 infection and intravenous drug use: longitudinal neuropsychological evaluation of asymptomatic subjects. Neurology. 1992;42(10):1924–1930.
   Web of Science ®Google Scholar
• Byrd DA, Fellows RP, Morgello S, et al. Neurocognitive Impact of Substance Use in HIV Infection. J Acquir Immune Defic Syndr. 2011;58(2):154–162.
   PubMed Web of Science ®Google Scholar
• Cook JA, Grey DD, Burke-Miller JK, et al. Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug Alcohol Depen. 2007;89(1):74–81.
   PubMed Web of Science ®Google Scholar
• Korthuis PT, Zephyrin LC, Fleishman JA, et al. Health-related quality of life in HIV-infected patients: the role of substance use. AIDS Patient Care STDS. 2008;22(11):859–867.
   PubMed Web of Science ®Google Scholar
• Goodkin K, Shapshak P, Metsch LR, et al. Cocaine abuse and HIV-1 infection: epidemiology and neuropathogenesis. J Neuroimmunol. 1998;83(1–2):88–101.
   PubMed Web of Science ®Google Scholar
• Chen GJ, Watson RR. Modulation of tumor necrosis factor and gamma interferon production by cocaine and morphine in aging mice infected with LP-BM5, a murine retrovirus. J Leuokocyte Biol. 1991;50(4):349–355.
   Web of Science ®Google Scholar
• Pellegrino T, Bayer BM. In vivo effects of cocaine on immune cell function. J Neuroimmunol. 1998;83(1–2):139–147.
   PubMed Web of Science ®Google Scholar
• Mao JT, Huang M, Wang J, Sharma S, Tashkin DP, Dubinett SM. Cocaine down-regulates IL-2-induced peripheral blood lymphocyte IL-8 and IFN-gamma production. Cell Immunol. 1996;172(2):217–223.
   Web of Science ®Google Scholar
• Mao JT, Zhu LX, Sharma S, et al. Cocaine inhibits human endothelial cell IL-8 production: the role of transforming growth factor-beta. Cell Immunol. 1997;181(1):38–43.
   Web of Science ®Google Scholar
• Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009;50(1):93–99.
   PubMed Web of Science ®Google Scholar
• Cook JA, Burke-Miller JK, Cohen MH, et al. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS. 2008;22(11):1355–1363.
   PubMed Web of Science ®Google Scholar
• Webber MP, Schoenbaum EE, Gourevitch MN, Buono D, Klein RS. A prospective study of HIV disease progression in female and male drug users. AIDS. 1999;13(2):257–262.
   PubMed Web of Science ®Google Scholar
• Baldwin GC, Roth MD, Tashkin DP. Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. J Neuroimmunol. 1998;83(1–2):133–138.
   Web of Science ®Google Scholar
• Cearley CN, Blindheim K, Sorg BA, Krueger JM, Churchill L. Acute cocaine increases interleukin-1beta mRNA and immunoreactive cells in the cortex and nucleus accumbens. Neurochem Res. 2011;36(4): 686–692.
   Web of Science ®Google Scholar
• Gurwell JA, Nath A, Sun Q, et al. Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro. Neuroscience. 2001;102(3):555–563.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yao H, Lu Y, Wang C, Buch S. Cocaine potentiates astrocyte toxicity mediated by human immunodeficiency virus (HIV-1) protein gp120. PloS One. 2010;5(10):e13427.
   Web of Science ®Google Scholar
• Aksenov MY, Aksenova MV, Nath A, Ray PD, Mactutus CF, Booze RM. Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology. 2006;27(2):217–228.
   PubMed Web of Science ®Google Scholar
• Turchan J, Anderson C, Hauser KF, et al. Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci. 2001;2:3.
   Web of Science ®Google Scholar
• Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178–201.
   PubMed Web of Science ®Google Scholar
• Dallasta LM, Pisarov LA, Esplen JE, et al. Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am J Pathol. 1999;155(6):1915–1927.
   Web of Science ®Google Scholar
• Gandhi N, Saiyed ZM, Napuri J, et al. Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder. J Neurovirol. 2010;16(4):294–305.
   PubMed Web of Science ®Google Scholar
• Zhang L, Looney D, Taub D, et al. Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirol. 1998;4(6):619–626.
   PubMed Web of Science ®Google Scholar
• Dhillon NK, Williams R, Peng F, et al. Cocaine-mediated enhancement of virus replication in macrophages: implications for human immunodeficiency virus-associated dementia. J Neurovirol. 2007;13(6): 483–495.
   PubMed Web of Science ®Google Scholar
• Fiala M, Eshleman AJ, Cashman J, et al. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J Neurovirol. 2005;11(3):281–291.
   PubMed Web of Science ®Google Scholar
• Fiala M, Gan XH, Zhang L, et al. Cocaine enhances monocyte migration across the blood-brain barrier. Cocaine’s connection to AIDS dementia and vasculitis? Adv Exp Med Biol. 1998;437:199–205.
   PubMed Web of Science ®Google Scholar
• Kanmogne GD, Primeaux C, Grammas P. HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIV-associated dementia. J Neuropath Exp Neur. 2005;64(6):498–505.
   PubMed Web of Science ®Google Scholar
• Yao H, Duan M, Buch S. Cocaine-mediated induction of platelet-derived growth factor: implication for increased vascular permeability. Blood. 2011;117(8):2538–2547.
   PubMed Web of Science ®Google Scholar
• Pan W XS, Tu H, Kastin A. Cytokines interact with the blood-brain barrier. In: Dermietzel R, Spray DC, Needergard M, editors. Blood-Brain Barriers. From Ontogeny to Artificial Interfaces. Weinheim: Wiley; 2006:247–264.
   Google Scholar
• Ernst T, Chang L, Oropilla G, Gustavson A, Speck O. Cerebral perfusion abnormalities in abstinent cocaine abusers: a perfusion MRI and SPECT study. Psychiat Res. 2000;99(2):63–74.
   Web of Science ®Google Scholar
• Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry. 2002;159(10):1642–1652.
   PubMed Web of Science ®Google Scholar
• Griffin WC 3rd, Middaugh LD, Tyor WR. Chronic cocaine exposure in the SCID mouse model of HIV encephalitis. Brain Res. 2007;1134(1): 214–219.
   Web of Science ®Google Scholar
• Yao H, Allen JE, Zhu X, Callen S, Buch S. Cocaine and human immunodeficiency virus type 1 gp120 mediate neurotoxicity through overlapping signaling pathways. J Neurovirol. 2009;15(2):164–175.
   Web of Science ®Google Scholar
• Chang L, Wang GJ, Volkow ND, et al. Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. NeuroImage. 2008;42(2):869–878.
   Web of Science ®Google Scholar
• Meade CS, Lowen SB, MacLean RR, Key MD, Lukas SE. fMRI brain activation during a delay discounting task in HIV-positive adults with and without cocaine dependence. Psychiat Res. 2011;192(3): 167–175.
   Web of Science ®Google Scholar
• Durvasula RS, Myers HF, Satz P, et al. HIV-1, cocaine, and neuropsychological performance in African American men. J Int Neuropsychol Soc. 2000;6(3):322–335.
   PubMed Web of Science ®Google Scholar
• Meade CS, Conn NA, Skalski LM, Safren SA. Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence. J Behav Med. 2011;34(2):128–138.
   PubMed Web of Science ®Google Scholar
• Martin EM, Sullivan TS, Reed RA, et al. Auditory working memory in HIV-1 infection. J Int Neuropsychol Soc. 2001;7(1):20–26.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Hardy DJ, Miller E, Castellon SA, Longshore D, Hinkin CH. The effect of recent stimulant use on sustained attention in HIV-infected adults. J Clin Exp Neuropsychol. 2006;28(1):29–42.
   PubMed Web of Science ®Google Scholar
• Halkitis PN, Parsons JT, Stirratt MJ. A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men. J Homosex. 2001;41(2):17–35.
   PubMed Web of Science ®Google Scholar
• Thiede H, Valleroy LA, MacKellar DA, et al. Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas. Am J Public Health. 2003;93(11):1915–1921.
   PubMed Web of Science ®Google Scholar
• Purcell DW, Moss S, Remien RH, Woods WJ, Parsons JT. Illicit substance use, sexual risk, and HIV-positive gay and bisexual men: differences by serostatus of casual partners. AIDS. 2005;19(Suppl 1):S37–S47.
   PubMed Web of Science ®Google Scholar
• Chan DJ. HIV-1 superinfection: evidence and impact. Curr HIV Res. 2004;2(3):271–274.
   Web of Science ®Google Scholar
• Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis. 2003;188(12):1820–1826.
   PubMed Web of Science ®Google Scholar
• Smith DM, Wong JK, Hightower GK, et al. HIV drug resistance acquired through superinfection. AIDS. 2005;19(12):1251–1256.
   Web of Science ®Google Scholar
• Reiner BC, Keblesh JP, Xiong H. Methamphetamine abuse, HIV infection, and neurotoxicity. Int J Physiol Pathophysiol Pharmacol. 2009;1(2):162–179.
   PubMedGoogle Scholar
• Liang H, Wang X, Chen H, et al. Methamphetamine enhances HIV infection of macrophages. Am J Pathol. 2008;172(6):1617–1624.
   Web of Science ®Google Scholar
• Gavrilin MA, Mathes LE, Podell M. Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J Neurovirol. 2002;8(3):240–249.
   PubMed Web of Science ®Google Scholar
• Yu Q, Zhang D, Walston M, Zhang J, Liu Y, Watson RR. Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice. Int Immunopharmacol. 2002;2(7):951–962.
   PubMed Web of Science ®Google Scholar
• Theodore S, Cass WA, Maragos WF. Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum. Exp Neurol. 2006;199(2):490–498.
   Web of Science ®Google Scholar
• Marcondes MC, Flynn C, Watry DD, Zandonatti M, Fox HS. Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys. Am J Pathol. 2010;177(1):355–361.
   PubMed Web of Science ®Google Scholar
• Rothrock JF, Rubenstein R, Lyden PD. Ischemic stroke associated with methamphetamine inhalation. Neurology. 1988;38(4):589–592.
   PubMed Web of Science ®Google Scholar
• Wang AM, Suojanen JN, Colucci VM, Rumbaugh CL, Hollenberg NK. Cocaine- and methamphetamine-induced acute cerebral vasospasm: an angiographic study in rabbits. Am J Neuroradiol. 1990;11(6): 1141–1146.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Zhang X, Manda KR, Banks WA, Ercal N. HIV proteins (gp120 and Tat) and methamphetamine in oxidative stress-induced damage in the brain: potential role of the thiol antioxidant N-acetylcysteine amide. Free Radic Biol Med. 2010;48(10):1388–1398.
   PubMed Web of Science ®Google Scholar
• Mahajan SD, Aalinkeel R, Sykes DE, et al. Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res. 2008;1203:133–148.
   PubMed Web of Science ®Google Scholar
• Cass WA, Harned ME, Peters LE, Nath A, Maragos WF. HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res. 2003;984(1–2):133–142.
   PubMed Web of Science ®Google Scholar
• Langford D, Grigorian A, Hurford R, Adame A, Crews L, Masliah E. The role of mitochondrial alterations in the combined toxic effects of human immunodeficiency virus Tat protein and methamphetamine on calbindin positive-neurons. J Neurovirol. 2004;10(6): 327–337.
   PubMed Web of Science ®Google Scholar
• Flora G, Lee YW, Nath A, Hennig B, Maragos W, Toborek M. Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp Neurol. 2003;179(1):60–70.
   PubMed Web of Science ®Google Scholar
• Chana G, Everall IP, Crews L, et al. Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology. 2006;67(8):1486–1489.
   PubMed Web of Science ®Google Scholar
• Langford D, Adame A, Grigorian A, et al. Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr. 2003;34(5):467–474.
   PubMed Web of Science ®Google Scholar
• Qi L, Gang L, Hang KW, et al. Programmed neuronal cell death induced by HIV-1 tat and methamphetamine. Microsc Res Tech. 2011. [Epub ahead of print.]
   Google Scholar
• Cai NS, Cadet JL. The combination of methamphetamine and of the HIV protein, Tat, induces death of the human neuroblastoma cell line, SH-SY5Y. Synapse. 2008;62(7):551–552.
   Web of Science ®Google Scholar
• Ances BM, Vaida F, Cherner M, et al. HIV and chronic methamphetamine dependence affect cerebral blood flow. J Neuroimmune Pharmacol. 2011;6(3):409–419.
   Web of Science ®Google Scholar
• Chang L, Ernst T, Speck O, Grob CS. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry. 2005;162(2):361–369.
   PubMed Web of Science ®Google Scholar
• Jernigan TL, Gamst AC, Archibald SL, et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychirtry. 2005;162(8):1461–1472.
   PubMed Web of Science ®Google Scholar
• Takaki M, Ujike H, Kodama M, Takehisa Y, Yamamoto A, Kuroda S. Increased expression of synaptophysin and stathmin mRNAs after methamphetamine administration in rat brain. Neuroreport. 2001; 12(5):1055–1060.
   Web of Science ®Google Scholar
• Taylor MJ, Schweinsburg BC, Alhassoon OM, et al. Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy. Journal of Neurovirol. 2007;13(2):150–159.
   Web of Science ®Google Scholar
• Rippeth JD, Heaton RK, Carey CL, et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc. 2004;10(1):1–14.
   PubMed Web of Science ®Google Scholar
• Carey CL, Woods SP, Rippeth JD, Gonzalez R, Heaton RK, Grant I. Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav. 2006;10(2):185–190.
   PubMed Web of Science ®Google Scholar
• Sadek JR, Vigil O, Grant I, Heaton RK. The impact of neuropsychological functioning and depressed mood on functional complaints in HIV-1 infection and methamphetamine dependence. J Clin Exp Neuropsychol. 2007;29(3):266–276.
   PubMed Web of Science ®Google Scholar
• Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol. 2002;63(2):179–186.
   PubMed Web of Science ®Google Scholar
• Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16(2):83–88.
   PubMed Web of Science ®Google Scholar
• Lefevre F, O’Leary B, Moran M, et al. Alcohol consumption among HIV-infected patients. J Gen Intern Med. 1995;10(8):458–460.
   PubMed Web of Science ®Google Scholar
• Petry NM. Alcohol use in HIV patients: what we don’t know may hurt us. Int J STD AIDS. 1999;10(9):561–570.
   PubMed Web of Science ®Google Scholar
• Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52(2):180–202.
   PubMed Web of Science ®Google Scholar
• Zarkin GA, Bray JW, Babor TF, Higgins-Biddle JC. Alcohol drinking patterns and health care utilization in a managed care organization. Health Serv Res. 2004;39(3):553–570.
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Conigliaro J, Roberts MS, et al. Estimating the impact of alcohol consumption on survival for HIV+ individuals. AIDS Care. 2007;19(4):459–466.
   PubMed Web of Science ®Google Scholar
• Fisher JC, Bang H, Kapiga SH. The association between HIV infection and alcohol use: a systematic review and meta-analysis of African studies. Sex Transm Dis. 2007;34(11):856–863.
   PubMed Web of Science ®Google Scholar
• Justus AN, Finn PR, Steinmetz JE. The influence of traits of disinhibition on the association between alcohol use and risky sexual behavior. Alcohol Clin Exp Res. 2000;24(7):1028–1035.
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Ho W, Ramirez SH, et al. HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. Brain Behav Immun. 2011;25(Suppl 1): S61–S70.
   Google Scholar
• Dingle GA, Oei TP. Is alcohol a cofactor of HIV and AIDS? Evidence from immunological and behavioral studies. Psych Bull. 1997;122(1): 56–71.
   PubMed Web of Science ®Google Scholar
• Meyerhoff DJ. Effects of alcohol and HIV infection on the central nervous system. Alcohol Res Health. 2001;25(4):288–298.
   PubMedGoogle Scholar
• Tyor WR, Middaugh LD. Do alcohol and cocaine abuse alter the course of HIV-associated dementia complex? J Leukoc Biol. 1999;65(4):475–481.
   PubMed Web of Science ®Google Scholar
• Alfonso-Loeches S, Pascual-Lucas M, Blanco AM, Sanchez-Vera I, Guerri C. Pivotal role of TLR4 receptors in alcohol-induced neuroinflammation and brain damage. J Neurosci. 2010;30(24):8285–8295.
   PubMed Web of Science ®Google Scholar
• Nelson S, Bagby GJ, Summer WR. Alcohol-induced suppression of tumor necrosis factor – a potential risk factor for secondary infection in the acquired immunodeficiency syndrome. Prog Clin Biol Res. 1990;325:211–220.
   Google Scholar
• Bagby GJ, Zhang P, Purcell JE, Didier PJ, Nelson S. Chronic binge ethanol consumption accelerates progression of simian immunodeficiency virus disease. Alcohol Clin Exp Res. 2006;30(10):1781–1790.
   Web of Science ®Google Scholar
• Kumar R, Perez-Casanova AE, Tirado G, et al. Increased viral replication in simian immunodeficiency virus/simian-HIV-infected macaques with self-administering model of chronic alcohol consumption. J Acquir Immune Defic. 2005;39(4):386–390.
   PubMed Web of Science ®Google Scholar
• Molina PE, Lang CH, McNurlan M, Bagby GJ, Nelson S. Chronic alcohol accentuates simian acquired immunodeficiency syndrome-associated wasting. Alcohol Clin Exp Res. 2008;32(1):138–147.
   PubMed Web of Science ®Google Scholar
• Marcondes MC, Watry D, Zandonatti M, Flynn C, Taffe MA, Fox H. Chronic alcohol consumption generates a vulnerable immune environment during early SIV infection in rhesus macaques. Alcohol Clin Exp Res. 2008;32(9):1583–1592.
   Web of Science ®Google Scholar
• Singh AK, Gupta S, Jiang Y. Oxidative stress and protein oxidation in the brain of water drinking and alcohol drinking rats administered the HIV envelope protein, gp120. J Neurochm. 2008;104(6): 1478–1493.
   Web of Science ®Google Scholar
• Acheampong E, Mukhtar M, Parveen Z, et al. Ethanol strongly potentiates apoptosis induced by HIV-1 proteins in primary human brain microvascular endothelial cells. Virology. 2002;304(2): 222–234.
   PubMed Web of Science ®Google Scholar
• Haorah J, Knipe B, Leibhart J, Ghorpade A, Persidsky Y. Alcohol-induced oxidative stress in brain endothelial cells causes blood-brain barrier dysfunction. J Leukoc Biol. 2005;78(6):1223–1232.
   PubMed Web of Science ®Google Scholar
• Haorah J, Ramirez SH, Schall K, Smith D, Pandya R, Persidsky Y. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. Journal Neurochm. 2007;101(2):566–576.
   Web of Science ®Google Scholar
• Pfefferbaum A, Rosenbloom MJ, Adalsteinsson E, Sullivan EV. Diffusion tensor imaging with quantitative fibre tracking in HIV infection and alcoholism comorbidity: synergistic white matter damage. Brain. 2007;130(Pt 1):48–64.
   Google Scholar
• Pfefferbaum A, Rosenbloom MJ, Rohlfing T, et al. Contribution of alcoholism to brain dysmorphology in HIV infection: effects on the ventricles and corpus callosum. Neuroimage. 2006;33(1):239–251.
   PubMed Web of Science ®Google Scholar
• Bornstein RA, Fama R, Rosenberger P, et al. Drug and alcohol use and neuropsychological performance in asymptomatic HIV infection. J Neuropsychiatry Clin Neurosci. 1993;5(3):254–259.
   PubMed Web of Science ®Google Scholar
• Fama R, Rosenbloom MJ, Nichols BN, Pfefferbaum A, Sullivan EV. Working and episodic memory in HIV infection, alcoholism, and their comorbidity: baseline and 1-year follow-up examinations. Alcohol Clin Exp Res. 2009;33(10):1815–1824.
   PubMed Web of Science ®Google Scholar
• Rothlind JC, Greenfield TM, Bruce AV, et al. Heavy alcohol consumption in individuals with HIV infection: effects on neuropsychological performance. J Int Neuropsychol Soc. 2005;11(1):70–83.
   PubMed Web of Science ®Google Scholar
• Green JE, Saveanu RV, Bornstein RA. The effect of previous alcohol abuse on cognitive function in HIV infection. Am J Psychiatry. 2004;161(2):249–254.
   PubMed Web of Science ®Google Scholar
• Schulte T, Mueller-Oehring EM, Rosenbloom MJ, Pfefferbaum A, Sullivan EV. Differential effect of HIV infection and alcoholism on conflict processing, attentional allocation, and perceptual load: evidence from a Stroop Match-to-Sample task. Biol Psychiatry. 2005;57(1): 67–75.
   PubMed Web of Science ®Google Scholar
• Sassoon SA, Fama R, Rosenbloom MJ, O’Reilly A, Pfefferbaum A, Sullivan EV. Component cognitive and motor processes of the digit symbol test: differential deficits in alcoholism, HIV infection, and their comorbidity. Alcohol Clin Exp Res. 2007;31(8): 1315–1324.
   Web of Science ®Google Scholar
• Durvasula RS, Myers HF, Mason K, Hinkin C. Relationship between alcohol use/abuse, HIV infection and neuropsychological performance in African American men. J Clin Exp Neuropsychol. 2006;28(3): 383–404.
   PubMed Web of Science ®Google Scholar
• Fairfield KM, Eisenberg DM, Davis RB, Libman H, Phillips RS. Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med. 1998;158(20):2257–2264.
   PubMed Web of Science ®Google Scholar
• Sidney S. Marijuana use in HIV-positive and AIDS patients: results of an anonymous mail survey. In: Russo E, editor. Cannabis Therapeutics in HIV/AIDS. New York, NY: Haworth Integrative Healing Press; 2001:35–41.
   Google Scholar
• Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515–521.
   PubMed Web of Science ®Google Scholar
• Corless IB, Lindgren T, Holzemer W, et al. Marijuana effectiveness as an HIV self-care strategy. Clin Nurs Res. 2009;18(2):172–193.
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34(3):672–680.
   PubMed Web of Science ®Google Scholar
• Davies SN, Pertwee RG, Riedel G. Functions of cannabinoid receptors in the hippocampus. Neuropharmacology. 2002;42(8):993–1007.
   Web of Science ®Google Scholar
• Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77(2):299–318.
   PubMed Web of Science ®Google Scholar
• Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87(5):1932–1936.
   PubMed Web of Science ®Google Scholar
• Bolla KI, Eldreth DA, Matochik JA, Cadet JL. Neural substrates of faulty decision-making in abstinent marijuana users. NeuroImage. 2005;26(2):480–492.
   PubMed Web of Science ®Google Scholar
• Eldreth DA, Matochik JA, Cadet JL, Bolla KI. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. NeuroImage. 2004;23(3):914–920.
   PubMed Web of Science ®Google Scholar
• Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology. 2006;185(3): 358–368.
   Web of Science ®Google Scholar
• Friedman H, Klein T, Specter S, et al. Drugs of abuse and virus susceptibility. Adv Biochem Psychopharmacol. 1988;44:125–137.
   Google Scholar
• Roth MD, Tashkin DP, Whittaker KM, Choi R, Baldwin GC. Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. Life Sci. 2005;77(14):1711–1722.
   PubMed Web of Science ®Google Scholar
• McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther. 2002;302(2):451–465.
   PubMed Web of Science ®Google Scholar
• Zhu LX, Sharma S, Stolina M, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokinedependent pathway. J Immunol. 2000;165(1):373–380.
   PubMed Web of Science ®Google Scholar
• Caiaffa WT, Vlahov D, Graham NM, et al. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. Am J Respir Crit Care Med. 1994;150(6 Pt 1): 1493–1498.
   Web of Science ®Google Scholar
• Lozada F, Silverman S Jr, Migliorati CA, Conant MA, Volberding PA. Oral manifestations of tumor and opportunistic infections in the acquired immunodeficiency syndrome (AIDS): findings in 53 homosexual men with Kaposi’s sarcoma. Oral Surg Oral Med Oral Pathol. 1983;56(5):491–494.
   Google Scholar
• Newell GR, Mansell PW, Wilson MB, Lynch HK, Spitz MR, Hersh EM. Risk factor analysis among men referred for possible acquired immune deficiency syndrome. Prev Med. 1985;14(1):81–91.
   Web of Science ®Google Scholar
• Rieg G, Lewis RJ, Miller LG, Witt MD, Guerrero M, Daar ES. Asymptomatic sexually transmitted infections in HIV-infected men who have sex with men: prevalence, incidence, predictors, and screening strategies. AIDS Patient Care STDS. 2008;22(12): 947–954.
   Web of Science ®Google Scholar
• Whitfield RM, Bechtel LM, Starich GH. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy. Alcohol Clin Exp Res. 1997;21(1):122–127.
   PubMed Web of Science ®Google Scholar
• Kuo WH, Wilson TE, Weber KM, et al. Initiation of regular marijuana use among a cohort of women infected with or at risk for HIV in the Women’s Interagency HIV Study (WIHS). AIDS Patient Care STDS. 2004;18(12):702–713.
   Web of Science ®Google Scholar
• Operskalski EA, Mack WJ, Strickler HD, et al. Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. J Clin Virol. 2008;41(4):255–263.
   Web of Science ®Google Scholar
• Tindall B, Cooper DA, Donovan B, et al. The Sydney AIDS Project: development of acquired immunodeficiency syndrome in a group of HIV seropositive homosexual men. Aust N Z J Med. 1988;18(1): 8–15.
   PubMedGoogle Scholar
• Chao C, Jacobson LP, Jenkins FJ, et al. Recreational drug use and risk of Kaposi’s sarcoma in HIV- and HHV-8-coinfected homosexual men. AIDS Res Hum Retroiruses. 2009;25(2):149–156.
   Web of Science ®Google Scholar
• D’Souza G, Palefsky JM, Zhong Y, et al. Marijuana use is not associated with cervical human papillomavirus natural history or cervical neoplasia in HIV-seropositive or HIV-seronegative women. Cancer Epidemiol Biomarkers Prev. 2010;19(3):869–872.
   Web of Science ®Google Scholar
• Wallace JM, Lim R, Browdy BL, et al. Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group. Chest. 1998;114(1):131–137.
   PubMed Web of Science ®Google Scholar
• Coates RA, Farewell VT, Raboud J, et al. Cofactors of progression to acquired immunodeficiency syndrome in a cohort of male sexual contacts of men with human immunodeficiency virus disease. Am J Epidemiol. 1990;132(4):717–722.
   PubMed Web of Science ®Google Scholar
• Di Franco MJ, Sheppard HW, Hunter DJ, Tosteson TD, Ascher MS. The lack of association of marijuana and other recreational drugs with progression to AIDS in the San Francisco Men’s Health Study. Ann Epidemiol. 1996;6(4):283–289.
   PubMed Web of Science ®Google Scholar
• Kaslow RA, Blackwelder WC, Ostrow DG, et al. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals. A report from the Multicenter AIDS Cohort Study. JAMA. 1989;261(23):3424–3429.
   PubMed Web of Science ®Google Scholar
• Bredt BM, Higuera-Alhino D, Shade SB, Hebert SJ, McCune JM, Abrams DI. Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol. 2002;42(11 Suppl):S82–S89.
   Web of Science ®Google Scholar
• Chao C, Jacobson LP, Tashkin D, et al. Recreational drug use and T lymphocyte subpopulations in HIV-uninfected and HIV-infected men. Drug Alcohol Dependen. 2008;94(1–3):165–171.
   Web of Science ®Google Scholar
• Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med. 2009;11:e3.
   PubMed Web of Science ®Google Scholar
• Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F. CB2 receptors in the brain: role in central immune function. Br J Pharmacol. 2008;153(2):240–251.
   PubMed Web of Science ®Google Scholar
• Centonze D, Finazzi-Agro A, Bernardi G, Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci. 2007;28(4):180–187.
   PubMed Web of Science ®Google Scholar
• Molina PE, Winsauer P, Zhang P, et al. Cannabinoid administration attenuates the progression of simian immunodeficiency virus. AIDS Res Hum Retroviruses. 2011;27(6):585–592.
   PubMed Web of Science ®Google Scholar
• Crean RD, Tapert SF, Minassian A, Macdonald K, Crane NA, Mason BJ. Effects of Chronic, Heavy Cannabis Use on Executive Functions. J Addict Med. 2011;5(1):9–15.
   Web of Science ®Google Scholar
• Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev. 2007;17(3):347–361.
   PubMed Web of Science ®Google Scholar
• Ranganathan M, D’Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology. 2006;188(4):425–444.
   PubMed Web of Science ®Google Scholar
• Cristiani SA, Pukay-Martin ND, Bornstein RA. Marijuana use and cognitive function in HIV-infected people. J Neuropsychiatry Clin Neurosci. 2004;16(3):330–335.
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Schuster RM, Vassileva J, Martin EM. Impact of HIV and a history of marijuana dependence on procedural learning among individuals with a history of substance dependence. J Clin Exp Neuropsychol. 2011;33(7):735–752.
   PubMed Web of Science ®Google Scholar
• Chang L, Cloak C, Yakupov R, Ernst T. Combined and independent effects of chronic marijuana use and HIV on brain metabolites. J Neuroimmune Pharmacol. 2006;1(1):65–76.
   PubMed Web of Science ®Google Scholar
• Jones R, Dunning J, Nelson M. HIV and hepatitis C co-infection. Int J Clin Pract. 2005;59(9):1082–1087.
   Web of Science ®Google Scholar
• Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antivir Res. 2010;85(1):303–315.
   PubMed Web of Science ®Google Scholar
• Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C coinfection within the CAESAR study. HIV Med. 2004;5(3):174–179.
   PubMed Web of Science ®Google Scholar
• Mohsen AH, Murad S, Easterbrook PJ. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London. HIV Med. 2005;6(3):206–215.
   PubMed Web of Science ®Google Scholar
• Verucchi G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection. 2004;32(1):33–46.
   PubMed Web of Science ®Google Scholar
• Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356(9244):1800–1805.
   PubMed Web of Science ®Google Scholar
• Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004;38(1):128–133.
   PubMed Web of Science ®Google Scholar
• Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450–456.
   PubMed Web of Science ®Google Scholar
• Forton DM, Thomas HC, Taylor-Robinson SD. Central nervous system involvement in hepatitis C virus infection. Metab Brain Dis. 2004;19(3–4):383–391.
   PubMed Web of Science ®Google Scholar
• Laskus T, Radkowski M, Bednarska A, et al. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol. 2002;76(19):10064–10068.
   PubMed Web of Science ®Google Scholar
• Bagaglio S, Cinque P, Racca S, et al. Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients. AIDS. 2005; 19(Suppl 3):S151–S165.
   Google Scholar
• Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol. 2004;78(10):5170–5183.
   Web of Science ®Google Scholar
• Letendre S, Paulino AD, Rockenstein E, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis. 2007;196(3):361–370.
   PubMed Web of Science ®Google Scholar
• Radkowski M, Wilkinson J, Nowicki M, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol. 2002;76(2):600–608.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Yang Y, Evans S. Neurologic consequences of hepatitis C and human immunodeficiency virus coinfection. J Neurovirol. 2005;11(Suppl 3):S67–S71.
   PubMedGoogle Scholar
• Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18(2):45–55.
   PubMedGoogle Scholar
• Martin-Thormeyer EM, Paul RH. Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev. 2009; 19(2):215–231.
   PubMed Web of Science ®Google Scholar
• Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep. 2011;8(1):12–22.
   PubMedGoogle Scholar
• Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet. 2001;358(9275):38–39.
   PubMed Web of Science ®Google Scholar
• Forton DM, Hamilton G, Allsop JM, et al. Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. J Hepatol. 2008;49(3):316–322.
   PubMed Web of Science ®Google Scholar
• Vivithanaporn P, Maingat F, Lin LT, et al. Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity. PloS one. 2010;5(9):e12856.
   Web of Science ®Google Scholar
• Clifford DB, Evans SR, Yang Y, Gulick RM. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS. 2005;19(Suppl 3):S64–S71.
   PubMed Web of Science ®Google Scholar
• Forton DM, Allsop JM, Cox IJ, et al. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS. 2005;19(Suppl 3):S53–S63.
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Jacobus J, Martin EM. Investigating neurocognitive features of hepatitis C virus infection in drug users: potential challenges and lessons learned from the HIV literature. Clin Infect Dis. 2005;41(Suppl 1):S45–S49.
   PubMedGoogle Scholar
• Hilsabeck RC, Castellon SA, Hinkin CH. Neuropsychological aspects of coinfection with HIV and hepatitis C virus. Clin Infect Dis. 2005;41(Suppl 1):S38–S44.
   Google Scholar
• Cherner M, Suarez P, Casey C, et al. Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. Dug Alcohol Depen. 2010;106(2–3):154–163.
   PubMed Web of Science ®Google Scholar
• Martin EM, Pitrak DL, Weddington W, et al. Cognitive impulsivity and HIV serostatus in substance dependent males. J Int Neuropsychol Soc. 2004;10(7):931–938.
   PubMed Web of Science ®Google Scholar
• Thiyagarajan A, Garvey LJ, Pflugrad H, et al. Cerebral function tests reveal differences in HIV-infected subjects with and without chronic HCV co-infection. Clin Microbiol Infect. 2010;16(10):1579–1584.
   PubMed Web of Science ®Google Scholar
• von Giesen HJ, Heintges T, Abbasi-Boroudjeni N, et al. Psychomotor slowing in hepatitis C and HIV infection. J Acquir Immune Defic Syndr. 2004;35(2):131–137.
   PubMed Web of Science ®Google Scholar
• Cherner M, Letendre S, Heaton RK, et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology. 2005;64(8):1343–1347.
   PubMed Web of Science ®Google Scholar
• van GorpWG, Hinkin CH. Triple trouble: cognitive deficits from hepatitis C, HIV, and methamphetamine. Neurology. 2005;64(8):1328–1329.
   Web of Science ®Google Scholar
• Center for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2009. Department of Health and Human Services, Centers for Disease Control and Prevention. Available from: http://www.cdc.gov/hiv/surveillance/resources/reports/2009report. Accessed Jul 2011.
   Google Scholar
• Center for Disease Control and Prevention. HIV Surveillance Report, 2008. Available from: http://www.cdc.gov/hiv/topics/surveillance. Accessed Jul 2011.
   Google Scholar
• Gardner ID. The effect of aging on susceptibility to infection. Rev Infect Dis. 1980;2(5):801–810.
   PubMedGoogle Scholar
• Saltzman RL, Peterson PK. Immunodeficiency of the elderly. Rev Infect Dis. 1987;9(6):1127–1139.
   PubMedGoogle Scholar
• Veugelers PJ, Strathdee SA, Kaldor JM, et al. Associations of age, immunosuppression, and AIDS among homosexual men in the Tricontinental Seroconverter Study. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14(5):435–441.
   PubMedGoogle Scholar
• Baker JV, Peng G, Rapkin J, et al. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr. 2008;48(5):541–546.
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Spritzler J, Chan E, et al. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acuir Immune Defic Syndr. 2006;42(4):426–434.
   Web of Science ®Google Scholar
• Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001;183(8):1290–1294.
   PubMed Web of Science ®Google Scholar
• Valcour V, Shikuma C, Shiramizu B, et al. Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. J Neuroimmunol. 2004;157(1–2):197–202.
   PubMed Web of Science ®Google Scholar
• Brew BJ, Crowe SM, Landay A, Cysique LA, Guillemin G. Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol. 2009;4(2):163–174.
   Web of Science ®Google Scholar
• Gelman BB, Schuenke K. Brain aging in acquired immunodeficiency syndrome: increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation. J Neurovirol. 2004;10:98–108.
   PubMed Web of Science ®Google Scholar
• Cao W, Jamieson BD, Hultin LE, Hultin PM, Effros RB, Detels R. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Defic Syndr. 2009;50(2):137–147.
   Web of Science ®Google Scholar
• Casau NC. Perspective on HIV infection and aging: emerging research on the horizon. Clin Infect Dis. 2005;41(6):855–863.
   Web of Science ®Google Scholar
• Kilpatrick RD, Rickabaugh T, Hultin LE, et al. Homeostasis of the naive CD4+ T cell compartment during aging. J Immunol. 2008; 180(6):1499–1507.
   Google Scholar
• Appay V, Fastenackels S, Katlama C, et al. Old age and anti-CMV immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS. 2011;25(15):1813–1822.
   PubMed Web of Science ®Google Scholar
• Rickabaugh TM, Kilpatrick RD, Hultin LE, et al. The dual impact of HIV-1 infection and aging on naive CD4 T-cells: additive and distinct patterns of impairment. PloS one. 2011;6(1):e16459.
   PubMed Web of Science ®Google Scholar
• Hoffman RM, Jamieson BD, Bosch RJ, et al. Baseline Immune Phenotypes and CD4+ T Lymphocyte Responses to Antiretroviral Therapy in Younger versus Older HIV-infected Individuals. J Clin Immunol. 2011;31(5):873–881.
   Web of Science ®Google Scholar
• Schacker TW, Bosch RJ, Bennett K, et al. Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV. J Acquir Immune Defic Syndr. 2010;54(1):59–62.
   Web of Science ®Google Scholar
• Ernst T, Chang L. Effect of aging on brain metabolism in antiretroviralnaive HIV patients. AIDS. 2004;18(Suppl 1):S61–S67.
   PubMedGoogle Scholar
• Chang L, Lee PL, Yiannoutsos CT, et al. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. NeuroImage. 2004;23(4):1336–1347.
   PubMed Web of Science ®Google Scholar
• Cherner M, Ellis RJ, Lazzaretto D, et al. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS. 2004;18(Suppl 1):S27–S34.
   PubMed Web of Science ®Google Scholar
• Valcour V, Paul R, Neuhaus J, Shikuma C. The Effects of Age and HIV on Neuropsychological Performance. J Int Neuropsychol Soc. 2011;17(1):190–195.
   PubMed Web of Science ®Google Scholar
• Becker JT, Lopez OL, Dew MA, Aizenstein HJ. Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS. 2004;18(Suppl 1):S11–S18.
   PubMed Web of Science ®Google Scholar
• Simone MJ, Appelbaum J. HIV in older adults. Geriatrics. 2008; 63(12):6–12.
   PubMed Web of Science ®Google Scholar
• Valcour VG, Shikuma CM, Watters MR, Sacktor NC. Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. AIDS. 2004;18(Suppl 1):S79–S86.
   PubMed Web of Science ®Google Scholar
• Wilkie FL, Goodkin K, Khamis I, et al. Cognitive functioning in younger and older HIV-1-infected adults. J Acquir Immune Defic Syndr. 2003;33(Suppl 2):S93–S105.
   Google Scholar
• Scott JC, Woods SP, Carey CL, Weber E, Bondi MW, Grant I. Neurocognitive Consequences of HIV Infection in Older Adults: An Evaluation of the “Cortical” Hypothesis. AIDS Behav. 2011;15(6):1187–1196.
   PubMed Web of Science ®Google Scholar
• Morgan EE, Woods SP, Delano-Wood L, Bondi MW, Grant I. Intraindividual variability in HIV infection: Evidence for greater neurocognitive dispersion in older HIV seropositive adults. Neuropsychology. 2011;25(5):645–654.
   PubMed Web of Science ®Google Scholar
• Ettenhofer ML, Hinkin CH, Castellon SA, et al. Aging, neurocognition, and medication adherence in HIV infection. Am J Geriatrc Psychiatry. 2009;17(4):281–290.
   PubMed Web of Science ®Google Scholar
• Malaspina L, Woods SP, Moore DJ, et al. Successful cognitive aging in persons living with HIV infection. J Neurovirol. 2011;17(1): 110–119.
   PubMed Web of Science ®Google Scholar
• Chilcoat HD, Breslau N. Investigations of causal pathways between PTSD and drug use disorders. Addict Behav. 1998;23(6):827–840.
   PubMed Web of Science ®Google Scholar
• Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psych. 2004;61(8):807–816.
   PubMed Web of Science ®Google Scholar
• Letendre SL, Cherner M, Ellis RJ, et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: Biological correlates of disease. AIDS. 2005;19(Suppl 3): S72–S78.
   PubMed Web of Science ®Google Scholar